Amgen (AMGN) Wins Otezla Patent Case
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Amgen (AMGN) Wins Ruling in Bid to Block Generic Otezla Until 2028, Loses Ruling on Otezla Patent That Expires in 2034 - Bloomberg
September 20, 2021 5:10 PM EDTAmgen (NASDAQ: AMGN) Wins Ruling in Bid to Block Generic Otezla Until 2028, Loses Ruling on Otezla Patent That Expires in 2034 - Bloomberg
... MoreVerastem (VSTM) and Amgen (AMGN) Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
September 20, 2021 7:05 AM EDTVerastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncologys investigational dual RAF/MEK inhibitor, with Amgens KRAS G12C inhibitor LUMAKRASTM (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC).
The Phase 1/2 trial will evaluate the safety, tolerability and efficacy of VS-6766 in combination with LUMAKRASTM in patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C... More
